Janet Pope, MD, MPH

Panelists discuss recent phase 3 trial results of a novel oral agent for idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), highlighting its ability to significantly reduce lung function decline and mortality—even when added to existing antifibrotic therapies—while maintaining a favorable safety and tolerability profile.

Panelists discuss exciting phase 3 trial data on a novel selective phosphodiesterase inhibitor that elevates intracellular cyclic AMP (cAMP) to activate anti-inflammatory and antifibrotic pathways, showing promise in slowing disease progression in idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF).

Panelists discuss several promising new agents for idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), including an LPA1 receptor antagonist showing lung function preservation, integrin inhibitors targeting fibrotic pathways despite safety challenges, and inhaled prostaglandins being evaluated as a well-tolerated add-on therapy in ongoing trials.

Panelists discuss how antifibrotic therapies for idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) slow disease progression despite challenges with cost, tolerability, and limited symptom relief, emphasizing the importance of patient education and aligning treatment goals.

Panelists discuss how effective management of idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) relies on early, accurate diagnosis and multidisciplinary collaboration, with a focus on personalized treatment strategies, proactive adverse effect management, and supportive interventions like pulmonary rehabilitation and nutrition to enhance quality of life and improve long-term outcomes.

Panelists discuss how managing idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) requires a comprehensive, patient-centered approach that addresses not only physiological decline but also the significant psychological, social, and functional burdens patients face—highlighting the need for early diagnosis, emotional support, and coordinated care to improve both quality of life and health care outcomes.

Panelists discuss how progressive pulmonary fibrosis (PPF) and idiopathic pulmonary fibrosis (IPF), though distinct in etiology, share a common trajectory of irreversible lung scarring and functional decline—highlighting the importance of recognizing progressive phenotypes across interstitial lung diseases to guide timely diagnosis, personalized treatment, and improved patient outcomes.

Panelists discuss how progressive pulmonary fibrosis (PPF) and idiopathic pulmonary fibrosis (IPF), though distinct in etiology, share a common trajectory of irreversible lung scarring and functional decline—highlighting the importance of recognizing progressive phenotypes across interstitial lung diseases to guide timely diagnosis, personalized treatment, and improved patient outcomes.

Panelists discuss how progressive pulmonary fibrosis (PPF) and idiopathic pulmonary fibrosis (IPF), though distinct in etiology, share a common trajectory of irreversible lung scarring and functional decline—highlighting the importance of recognizing progressive phenotypes across interstitial lung diseases to guide timely diagnosis, personalized treatment, and improved patient outcomes.

Panelists discuss how idiopathic pulmonary fibrosis (IPF), a progressive and often fatal interstitial lung disease, presents significant clinical challenges due to its variable trajectory, limited treatment options, and poor prognosis—underscoring the importance of early diagnosis and specialized care and the need for therapies that can more effectively alter disease progression.